Rhofade Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber of Rhofade (oxymetazoline hydrochloride cream, 1%), you may be fielding calls from patients who cannot fill their prescription at local pharmacies. While there is no active FDA-designated shortage of Rhofade as of 2026, access barriers — from pharmacy stocking gaps to prior authorization delays — are creating real disruptions for patients. This briefing covers the current landscape and practical strategies for your practice.

Current Availability Status (2026)

Rhofade is not in an FDA-designated shortage as of 2026. Mayne Pharma is the current commercial manufacturer and distributor in the U.S. However, several structural factors make Rhofade consistently difficult for patients to fill:

No approved generic: Single-source supply from Mayne Pharma with no generic competitors. Patent exclusivity extends at least through 2027.

High WAC: Wholesale acquisition cost is approximately $340 per 15g tube, with retail prices frequently exceeding $800. Many pharmacies limit inventory due to carrying cost.

Niche demand: Rhofade prescriptions are concentrated in dermatology practices. General retail pharmacies often stock it minimally or on-order-only basis, causing delays.

Prior Authorization Burden for Rhofade

Most major payers require prior authorization (PA) for Rhofade. Key payer requirements as of 2026:

UnitedHealthcare: PA required. Approval typically for 12 months. Reauthorization requires documentation of positive clinical response.

Cigna: PA required per their Topical Alpha-Adrenergic Agonists policy. Criteria include diagnosis of rosacea with persistent facial erythema documented by the prescriber.

State Medicaid: Coverage and PA requirements vary by state. Minnesota Medicaid, for example, requires documentation that the prescriber has reviewed drug interactions and will monitor the patient.

Medicare Part D: Coverage is limited and varies by plan. Many Part D plans do not cover Rhofade or classify it at a high tier.

PA documentation typically required: diagnosis of rosacea with persistent facial erythema, confirmation that first-line agents have been inadequate or are contraindicated, and prescriber attestation to review of drug interactions.

Clinical Alternatives When Rhofade Is Inaccessible

When patients cannot access Rhofade due to pharmacy unavailability or insurance denial, consider these evidence-based alternatives:

Mirvaso (brimonidine tartrate 0.33% gel): Direct class alternative (alpha-2 agonist), FDA-approved for rosacea erythema. Note: some patients experience rebound flushing that does not occur with Rhofade.

Finacea (azelaic acid 15% gel/foam): Generic available, anti-inflammatory mechanism, effective for both erythema and inflammatory lesions. Better long-term disease modification.

Soolantra (ivermectin 1% cream): FDA-approved for inflammatory rosacea lesions; meta-analyses show superior efficacy vs. metronidazole for lesion reduction.

Topical metronidazole 0.75% (MetroGel and generics): Long-established rosacea therapy; generic widely available and affordable. Less effective for isolated erythema but good for inflammatory component.

Low-dose doxycycline 40mg (Oracea): Oral anti-inflammatory for moderate-to-severe papulopustular rosacea. Evidence-based and widely available.

Savings Programs to Improve Patient Access

When Rhofade is the preferred agent and access is primarily a cost barrier, the Mayne Pharma Copay Savings Card (RWET program) can reduce patient out-of-pocket to as low as $0 for commercially insured patients. The card is not available for Medicare, Medicaid, or other government insurance beneficiaries. Direct patients to rhofade.com or call 347-442-7919 to access the savings card.

43,100+ patients found their medications in stock

43K+

Find Rhofade In Stock Today →

How medfinder Can Help Your Patients

Consider recommending medfinder for providers as a resource for patients struggling to fill Rhofade. Patients provide their medication, dosage, and location; medfinder contacts pharmacies and texts them results showing which locations can fill the prescription. This reduces phone calls to your office and helps patients get their medication without unnecessary delays.

Documentation Recommendations

For efficient PA processing, ensure your documentation includes: ICD-10 code L71.9 (Rosacea, unspecified) or L71.0 (Perioral dermatitis) as appropriate, clinical description of persistent facial erythema severity, and any prior treatments tried. Pre-emptively including this in initial PA submissions reduces back-and-forth with payers and speeds approval for your patients.

For a step-by-step guide on supporting patients through Rhofade access challenges, see our provider guide to helping patients find Rhofade in stock.